∙ For non-Hodgkin Lymphomas (B-NHL):

• Provision of signed Informed Consent form;

• Age between 18 and 70 years;

• Performance status according to the Eastern Cooperative Oncology Group \< 2;

• Relapsed or refractory B-NHL of the following types (confirmed by biopsy):

‣ Diffuse large B-cell lymphoma (DLBCL, NOS);

⁃ High-grade B-cell lymphoma (HGBCL);

⁃ Diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL-2 rearrangement;

⁃ Follicular lymphoma (FL) grade 3B; or

⁃ Transformed follicular lymphoma (tFL)

• Refractory or relapsed to two or more lines of systemic therapy, with at least one scheme containing an anti-CD20 monoclonal antibody and anthracycline, as defined below:

‣ Refractoriness: partial response (PR), stable disease (SD), or progressive disease (PD) as the best response to the last treatment, assessed by PET-CT, according to the Lugano criteria and confirmed by a new biopsy.

⁃ Relapsed disease: disease reappearance after obtaining a complete response to the last treatment, assessed by PET-CT, according to the Lugano criteria and confirmed by a new biopsy.

• Have performed, or be ineligible for, autologous hematopoietic progenitor cell transplantation (ASCT). Ineligibility is defined by:

‣ Lack of at least partial response after salvage chemotherapy; or

⁃ Failure to mobilize and/or collect hematopoietic progenitor cells (HPC), as defined by the investigator.

• Measurable disease, defined as:

‣ Nodal lesions \>15 mm in the long axis, regardless of the length of the short axis, and/or

⁃ Extranodal lesions (outside lymph node or nodal mass, but including liver and spleen) \>10 mm in long axis, regardless of the length of the short axis.

• Adequate organ function:

∙ Renal function defined as:

• estimated glomerular filtration rate (eGFR) ≥ 40 mL/min/1.73 m2

∙ Hepatic function defined as:

• Alanine Transaminase (ALT) and Aspartate Transaminase (AST) ≤ 2.5 × ULN; and

• Total bilirubin ≤ 1.5 × ULN, except for patients with Gilbert syndrome.

∙ Hematologic Function (regardless of transfusions for 14 days) defined as:

• Absolute neutrophil count (ANC) \>500/uL

• Platelets ≥ 50,000/uL

• Hemoglobin \>7.0 g/dl

‣ In women of childbearing potential, willingness to use effective means of birth control for 1 year after CAR-T cell infusion.

⁃ In male participants, willingness to use a barrier birth control method for 1 year after CAR-T cell infusion

⁃ Able to comply with inpatient treatment, outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation.

∙ For Acute Lymphoblastic Leukemia (B-ALL):

• Provision of signed Informed Consent form;

• Age ≥ 3 and \< 25 years;

• Performance status \< 2, according to the Eastern Cooperative Oncology Group for patients ≥ 16 years old, or ≥ 50%, according to the Lansky performance status for patients younger than 16 years old;

• Relapsed or refractory CD19 positive B-ALL, with documentation of CD19 disease expression within 3 months of screening visit.

• Relapsed or refractory disease as defined below;

‣ Failure to obtain hematologic complete remission (bone marrow with \< 5% lymphoblasts by morphologic assessment) after 2 distinct chemotherapy lines; or

⁃ Relapsed or refractoriness after at least 1 previous chemotherapy regimen and ineligibility for allogeneic hematopoietic progenitor cell transplantation (HSCT) due to lack of available donor (including alternative donors), comorbidity, have previously undergone or refused HSCT; or

⁃ Relapsed disease ≥ 6 months after HSCT; or

⁃ Relapsed or refractoriness after ≥ TKi for Philadelphia-positive B-ALL.

• Bone marrow with ≥ 5% lymphoblasts by morphologic assessment within 30 days from screening

• Adequate organ function:

∙ Renal function defined as:

• Estimated glomerular filtration rate (eGFR) ≥ 40 mL/min/1.73 m2

∙ Hepatic function defined as:

• Alanine Transaminase (ALT) and Aspartate Transaminase (AST) ≤ 5 × ULN; and

• Total bilirubin ≤ 2 × ULN, except for patients with Gilbert syndrome.

‣ In women of childbearing potential, willingness to use effective means of birth control for 1 year after CAR-T cell infusion.

⁃ In male participants, willingness to use a barrier birth control method for 1 year after CAR-T cell infusion

⁃ Able to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation. duration of the parent study and the long-term follow-up observational study